These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37728861)

  • 21. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
    Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
    Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States.
    Edgerton C; Frick A; Helfgott S; Huston KK; Singh JA; Zueger P; Anyanwu SI; Patel P; Soloman N
    ACR Open Rheumatol; 2024 Apr; 6(4):179-188. PubMed ID: 38221639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice.
    Werner SG; Baraliakos X; Reckert S; Bohl-Bühler M; Laliberté MC; Girard T; Jeromin K; Baschuk N; Fritz B; Bessette L; Hueber AJ
    Rheumatol Ther; 2023 Dec; 10(6):1503-1518. PubMed ID: 37695506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.
    Bergman M; Chen N; Thielen R; Zueger P
    Adv Ther; 2023 Oct; 40(10):4493-4503. PubMed ID: 37542646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of patient-reported outcomes in the assessment of rheumatoid arthritis disease activity:the experience of the ESPOIR cohort.
    Che H; Combe B; Morel J; Cantagrel A; Gossec L; Lukas C
    Clin Exp Rheumatol; 2016; 34(4):646-54. PubMed ID: 27384748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
    van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V
    Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving Quality of Care in Rheumatoid Arthritis Through Mobile Patient-Reported Outcome Measurement: Focus Group Study.
    Desai S; Stevens E; Emani S; Meyers P; Iversen M; Solomon DH
    JMIR Form Res; 2020 May; 4(3):e15158. PubMed ID: 32459179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.
    Singh H; Gupta V; Ray S; Kumar H; Talapatra P; Kaur M; Kumar S; Arya S; Mathur R; Ghangas N
    Clin Rheumatol; 2012 Dec; 31(12):1663-9. PubMed ID: 22983768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sites.
    El-Haddad C; Castrejon I; Gibson KA; Yazici Y; Bergman MJ; Pincus T
    RMD Open; 2017; 3(1):e000391. PubMed ID: 29225915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.
    Harrold LR; John A; Best J; Zlotnick S; Karki C; Li Y; Greenberg JD; Kremer JM
    Clin Rheumatol; 2017 Sep; 36(9):2135-2140. PubMed ID: 28718043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
    Shimizu T; Kawashiri SY; Sato S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Morimoto S; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2022 Jan; 101(2):e28463. PubMed ID: 35029189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count.
    Germain G; Worley K; MacKnight SD; Rubin B; Bell CF; Laliberté F; Urosevic A; Sheng Duh M; Concoff A
    Lupus Sci Med; 2024 Apr; 11(1):. PubMed ID: 38575172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.